[go: up one dir, main page]

WO2002072126A3 - Invention concernant les maladies induites par le virus de l'hepatite c - Google Patents

Invention concernant les maladies induites par le virus de l'hepatite c Download PDF

Info

Publication number
WO2002072126A3
WO2002072126A3 PCT/DE2002/000871 DE0200871W WO02072126A3 WO 2002072126 A3 WO2002072126 A3 WO 2002072126A3 DE 0200871 W DE0200871 W DE 0200871W WO 02072126 A3 WO02072126 A3 WO 02072126A3
Authority
WO
WIPO (PCT)
Prior art keywords
hcv
binding partners
protein
diseases
invention relating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DE2002/000871
Other languages
German (de)
English (en)
Other versions
WO2002072126A2 (fr
Inventor
Norbert Tautz
Christoph Birghan
Heinz-Juergen Thiel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transmit Gesellschaft fuer Technologietransfer mbH
Original Assignee
Transmit Gesellschaft fuer Technologietransfer mbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transmit Gesellschaft fuer Technologietransfer mbH filed Critical Transmit Gesellschaft fuer Technologietransfer mbH
Priority to AU2002257525A priority Critical patent/AU2002257525A1/en
Publication of WO2002072126A2 publication Critical patent/WO2002072126A2/fr
Publication of WO2002072126A3 publication Critical patent/WO2002072126A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des partenaires de liaison pour la protéine NS2 du virus de l'hépatite C humain (HCV), des partenaires de liaison pour une protéine du domaine J cellulaire (Jiv = protéine du domaine J interagissant avec la protéine virale), un procédé d'identification des partenaires de liaison qui provoquent une inhibition compétitive ou allostérique de la liaison entre la protéine HCV-NS2 et la Jiv, des agents utilisés pour traiter les maladies induites par le HCV, lesquels contiennent ces partenaires de liaison, ainsi que l'utilisation de ces partenaires de liaison pour la prévention, le diagnostic et le traitement de maladies induites par le HCV.
PCT/DE2002/000871 2001-03-14 2002-03-13 Invention concernant les maladies induites par le virus de l'hepatite c Ceased WO2002072126A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002257525A AU2002257525A1 (en) 2001-03-14 2002-03-13 Invention relating to hcv diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10112748A DE10112748A1 (de) 2001-03-14 2001-03-14 Erfindung betreffend HCV-Erkrankungen
DE10112748.0 2001-03-14

Publications (2)

Publication Number Publication Date
WO2002072126A2 WO2002072126A2 (fr) 2002-09-19
WO2002072126A3 true WO2002072126A3 (fr) 2002-11-14

Family

ID=7677752

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2002/000871 Ceased WO2002072126A2 (fr) 2001-03-14 2002-03-13 Invention concernant les maladies induites par le virus de l'hepatite c

Country Status (3)

Country Link
AU (1) AU2002257525A1 (fr)
DE (1) DE10112748A1 (fr)
WO (1) WO2002072126A2 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0468527A2 (fr) * 1990-07-26 1992-01-29 United Biomedical, Inc. Peptides synthétiques, spécifiques pour le dépistage d'anticorps contre HCV, pour la diagnose de l'infection causée par HCV et sa prévention en tant que vaccins
JPH06141870A (ja) * 1992-03-12 1994-05-24 Tokyo Met Gov Rinshiyou Igaku Sogo Kenkyusho 非ａ非ｂ型肝炎ウイルス抗原をコードするｄｎａ断片
WO1994014974A1 (fr) * 1992-12-29 1994-07-07 Akzo Nobel N.V. Anticorps monoclonaux et anticorps anti-idiotypes diriges contre le virus de l'hepatite c
EP0939128A2 (fr) * 1989-09-15 1999-09-01 Oya, Akira, Dr., Director General of the National Institute of Health of Japan, on behalf of The National Institute of Japan Isolats de VHC
WO2001016379A1 (fr) * 1999-08-30 2001-03-08 Merck & Co., Inc. Inhibiteurs de replication du virus de l'hepatite c

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0939128A2 (fr) * 1989-09-15 1999-09-01 Oya, Akira, Dr., Director General of the National Institute of Health of Japan, on behalf of The National Institute of Japan Isolats de VHC
EP0468527A2 (fr) * 1990-07-26 1992-01-29 United Biomedical, Inc. Peptides synthétiques, spécifiques pour le dépistage d'anticorps contre HCV, pour la diagnose de l'infection causée par HCV et sa prévention en tant que vaccins
JPH06141870A (ja) * 1992-03-12 1994-05-24 Tokyo Met Gov Rinshiyou Igaku Sogo Kenkyusho 非ａ非ｂ型肝炎ウイルス抗原をコードするｄｎａ断片
WO1994014974A1 (fr) * 1992-12-29 1994-07-07 Akzo Nobel N.V. Anticorps monoclonaux et anticorps anti-idiotypes diriges contre le virus de l'hepatite c
WO2001016379A1 (fr) * 1999-08-30 2001-03-08 Merck & Co., Inc. Inhibiteurs de replication du virus de l'hepatite c

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DARKE P L ET AL: "INHIBITION OF HEPATITIS C VIRUS NS2/3 PROCESSING BY NS4A PEPTIDES", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 274, no. 49, 3 December 1999 (1999-12-03), pages 34511 - 34514, XP002934074, ISSN: 0021-9258 *
PATENT ABSTRACTS OF JAPAN vol. 018, no. 448 (C - 1240) 22 August 1994 (1994-08-22) *

Also Published As

Publication number Publication date
AU2002257525A1 (en) 2002-09-24
DE10112748A1 (de) 2002-09-19
WO2002072126A2 (fr) 2002-09-19

Similar Documents

Publication Publication Date Title
CY2020003I1 (el) Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις για την θεραπευτικη αγωγη της παθολογιας του crohn
WO2006041970A3 (fr) Infection a virus respiratoire syncytial (rsv)
WO2003057134A8 (fr) Agents de liaison specifiques de l'angiopoietine-2 humaine
WO2002074337A8 (fr) Inhibiteurs et/ou antagonistes de proteines hmgb1 destines au traitement de maladies vasculaires
FR16C0028I2 (fr) Vecteurs viraux et utilisation de ces derniers dans des methodes therapeutiques
WO2003101401A3 (fr) Utilisation de nrg4, ou d'inhibiteurs de nrg4, dans le traitement du cancer du colon et du pancreas
DE60137337D1 (de) Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene
ATE315938T1 (de) 4'-substituierte nukleoside zur behandlung von hepatitis-c-virus-vermittelten erkrankungen
MXPA03006728A (es) Combinaciones de inhibidor(es) de la absorcion de esterol con modificador(es) sanguineos para tratar cuadros vasculares.
BRPI0307673A2 (pt) métodos de tratar doença vascular.
WO2004006858A3 (fr) Composes, compositions et methodes d'utilisation de ces derniers
ATE350375T1 (de) 17beta-hydroxysteroid dehydrogenase type 3 inhibitoren zur behandlung von androgen- abhängigen erkrankungen
WO2004028454A3 (fr) 1, 3, 5-triazines destinees au traitement de maladies virales
WO2004002940A8 (fr) Inhibiteurs de la polymerase du vhc (ns5b)
DE60234760D1 (de) Phenylindole zur behandlung von hiv
PT1427409E (pt) Métodos para tratar ou para impedir a inflamação vascular utilizando inibidor(es) de absorção de esteróis
WO2005002526A3 (fr) Procedes et compositions pour le traitement d'infections virales
WO2004091436A3 (fr) Procedes et compositions permettant de traiter des maladies oculaires
DE60016047D1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
MXPA03006776A (es) Uso de inhibidores de interleucina-18 para el tratamiento y/o prevencion de enfermedad cardiaca.
EP1765330A4 (fr) Derives de pyranoindole et utilisation de ceux-ci pour le traitement d'une maladie ou d'une infection provoquee par le virus de l'hepatite c
WO2002055560A3 (fr) Anticorps monoclonaux specifiques a la glycoproteine e2 du virus de l'hepatite c et leurs utilisations dans le diagnostic, le traitement et la prevention de l'hepatite c
DK1689410T3 (da) Forebyggelse og behandling af hypertensive hjertesygdomme ved de selektive östrogener 8beta-vinyl-estra-1,3,5(10)-trien-3,17beta-diol og 17beta-fluor-9alpha-vinyl-estra-1,3,5(10)-trien-3,16alpha-diol
WO2001007479A3 (fr) Matieres vivantes et methodes utiles pour le diagnostic ou le traitement de maladies
DK1530462T3 (da) 1-phenyl-2-dimethylaminomethylcyclohexanforbindelser til behandling af depressionssymtomer. smerte og inkontinens

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA CN JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA CN JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP